Skip to main content
Click to go back to the Pipeline page Back To Explore Our Pipeline
Click to go back to the Pipeline page Back to
Pipeline

Disable motion

XB371:
TF-TOPOi
ADC

XB371 is a novel anti-TF antibody-drug conjugate composed of a TOPOi payload that is internalized, translocates to endocytic compartments, and co-localizes with lysosomal-associated membrane protein 1 in the A431 cancer cell line. XB371 has demonstrated in vitro cell killing properties across multiple xenograft cancer cell lines that express TF, in vitro bystander activity, in vitro immune cell activation, and in vivo efficacy in TF-expressing pancreatic xenograft models and PDX models that include NSCLC and low TF-expressing CRC, supporting its further clinical development by Exelixis.
Molecular structure shown is an artistic rendering.
MECHANISM
OF ACTION
Tissue factor (TF) is a transmembrane glycoprotein that plays an important role in the extrinsic coagulation cascade. TF is aberrantly expressed in multiple tumors including ovarian, cervical, urogenital, non-small cell lung, squamous cell carcinoma of the head and neck, and pancreatic cancers. TF expression is generally associated with poor disease outcomes. XB371 is an anti-TF antibody drug conjugate composed of a tandem-cleavage topoisomerase inhibitor (TOPOi)–based linker-payload site-specifically conjugated to a monoclonal antibody (mAb) that binds to TF on the surface of tumor cells with high affinity without interfering with the clotting cascade in cell-based assays, resulting in tumor cell death.
XB371
CLINICAL TRIAL
INFORMATION
Phase 1 dose-escalation and expansion study of XB371 in locally advanced or metastatic solid tumors.
For more information, visit
https://clinicaltrials.gov/study/ NCT07123103
This website includes information on investigational uses of compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.
Explore All
Pipeline Clinical Trials